

# Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes

Is this of concern?

LOUIS MONNIER, MD<sup>1</sup>  
CLAUDE COLETTE, PHD<sup>1</sup>

SYLVIE DEJAGER, MD, PHD<sup>2</sup>  
DAVID OWENS, MD<sup>3</sup>

**OBJECTIVE**—To assess the magnitude of the dawn phenomenon and its impact on the total glucose exposure in type 2 diabetes.

**RESEARCH DESIGN AND METHODS**—A total of 248 noninsulin-treated persons with type 2 diabetes who underwent continuous glucose monitoring were divided into three groups selected by treatments: diet alone ( $n = 53$ ); insulin sensitizers alone ( $n = 82$ ); and insulin secretagogues alone or in combination with insulin sensitizers ( $n = 113$ ). The dawn phenomenon ( $\Delta$  glucose, mg/dL) was quantified by its absolute increment from nocturnal nadir to prebreakfast value. The participants were secondarily divided into two paired subsets after they had been separated by the presence/absence of a dawn phenomenon based on a threshold of 20 mg/dL and matched for glucose nadir. The impact of the dawn phenomenon was assessed on HbA<sub>1c</sub> and 24-h mean glucose.

**RESULTS**—The median of  $\Delta$  glucose (interquartile range) was 16.0 (0–31.5 mg/dL) in the 248 subjects, and no differences were observed across groups selected by HbA<sub>1c</sub> or treatments. In the overall population, the mean impacts on HbA<sub>1c</sub> and 24-h mean glucose were  $4.3 \pm 1.3$  mmol/mol (0.39  $\pm$  0.12%) and  $12.4 \pm 2.4$  mg/dL, respectively. The mean impact on 24-h mean glucose was not statistically different between those on diet alone ( $16.7 \pm 5.9$  mg/dL) compared with the two subsets treated with oral hypoglycemic agents ( $11.2 \pm 5.3$  and  $8.5 \pm 7.5$  mg/dL).

**CONCLUSIONS**—The impact of the dawn phenomenon on overall glycemic control in type 2 diabetes, as depicted by the HbA<sub>1c</sub> level, was  $\sim 0.4\%$  and not eliminated by any of the currently available armamentarium of oral antidiabetes agents.

*Diabetes Care* 36:4057–4062, 2013

The term “dawn phenomenon” was introduced by Schmidt et al. (1) in the early 1980s. Within a few years, it became obvious that this phenomenon corresponded to a spontaneous rise in plasma glucose and/or insulin requirements toward the end of the nocturnal period, in the absence of any intake of dietary carbohydrates (2). The dawn phenomenon was initially regarded as a causative factor for glucose instability, and although there are many uncertainties about its impact on overall glycemic control, these have never been adequately

addressed. There are several potential reasons that can contribute to this deficiency. One of the main reasons resides in the fact that the definition is based on a dawn increment in glucose levels from the nocturnal nadir to the prebreakfast glucose value. As a consequence, the quantification of the dawn phenomenon requires accurate detection of the nocturnal nadir glucose concentration. Such determinations only became possible with the advent of continuous ambulatory interstitial glucose monitoring (CGM) (3,4), which permits the calculation of the absolute

differences between the nocturnal nadirs and the prebreakfast glucose values. The current study was therefore designed using CGM to revisit the dawn phenomenon, which continues to remain a subject of debate (5–9). The first objective was to gain further insight into the assessment of its magnitude in a large group of persons with type 2 diabetes, using CGM on an ambulatory basis in real-life conditions on 2 consecutive days. In addition, we set out to explore the impact of the dawn phenomenon on the overall glucose exposure that was assessed both by the HbA<sub>1c</sub> levels and 24-h mean glucose concentrations calculated from the CGM using the average of 2 consecutive days to account for the interday fluctuations of the dawn phenomenon at an individual level. Should the current study be able to show that the presence or absence of the dawn phenomenon resulted in differences in glycemic control, this might incite health care providers to assess for and devise therapeutic strategies to avoid this phenomenon in an attempt to achieve better overall glycemic control in subjects with type 2 diabetes.

## RESEARCH DESIGN AND METHODS

This study was conducted in a total of 248 persons with type 2 diabetes who were selected for final analysis after screening for eligibility among a total population of 292 subjects who underwent 3-day ambulatory CGM. Criteria of exclusion from the initial screened list of potential participants included those who had a HbA<sub>1c</sub> level  $\geq 86$  mmol/mol ( $\geq 10\%$ ) and/or had experienced a recent illness or been treated with steroids during the 3-month period preceding the investigation. In addition, exclusion criteria from the final analysis were unexpected disruption in the glucose monitoring or insufficient number of blood glucose tests for the calibration of the CGM (four tests were required daily for this purpose). Unacceptable calibration meant an accuracy criterion with a correlation

From the <sup>1</sup>Institute of Clinical Research, University Montpellier 1, Montpellier, France; the <sup>2</sup>Department of Endocrinology, Hospital Pitié Salpêtrière, Paris, France; and the <sup>3</sup>Diabetes Research Group, Swansea University, Swansea, U.K.

Corresponding author: Louis Monnier, louis.monnier@inserm.fr.

Received 18 October 2012 and accepted 10 July 2013.

DOI: 10.2337/dc12-2127

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

See accompanying commentary, p. 3860.

coefficient of  $<0.79$  (35 patients out of 292 [i.e., 12.0%]). Finally, we excluded all participants who reported at least one clinical hypoglycemic event over the test period in order to avoid any false interpretation of glucose rises in the early morning.

All participants were investigated from 2003 to 2011 at the outpatient clinics of either the University Hospital (Montpellier, France) for 198 subjects or the Diabetes Research Unit (Cardiff, U.K.) for 50 subjects with type 2 diabetes. All participants had been on a stable treatment regimen with dietary measures alone or with the addition of oral hypoglycemic agents (OHAs) for at least 3 months prior to CGM. Modalities of treatment were classified into three categories: 1) dietary measures alone ( $n = 53$ ); 2) insulin sensitizers alone (metformin and/or thiazolidinediones) ( $n = 82$ ); and 3) insulin secretagogues (sulfonylureas, glinides, or dipeptidyl peptidase-4 inhibitors) alone or in combination with an insulin sensitizer ( $n = 113$ ). Dietary measures were based on a weight-maintaining diet with three main meals per day and with carbohydrates providing 50% of the total daily energy intake. Energy intake was assumed to be equal to total energy expenditure. The latter was determined by calculating the basal metabolic rate from the Schofield equations (10) and then by multiplying this result by 1.35, a coefficient that corresponds to a sedentary lifestyle with a poor physical activity in most of our patients. A daily ratio of 1:2:2 was recommended for calorie and carbohydrate distribution among breakfast, lunch, and dinner, respectively. The expected mean daily energy and carbohydrate intakes as estimated from this calculation are given in Table 1. At the beginning and end of each 3-day study period, dietary recommendations were carefully repeated and validated by trained dietitians, and instructions were given to patients for following their routine low-level physical activity and avoiding any vigorous exercise. All of the investigations were performed in routine diabetes outpatient clinics and were in compliance with the Helsinki Declaration (11). The study was conducted after each subject had given an oral informed consent in accordance with European directives that require no approval from an ethics committee for the noninterventional design as described herein (12).

### **Clinical investigations and laboratory determinations**

All participants underwent ambulatory CGM for 3 consecutive days using the same technology from 2003 to 2011 (i.e., a second-generation MiniMed system [Medtronic, Northridge, CA]) following training in the use of the device. The sensor was inserted on day 0 and removed midmorning on day 3. Insertion of CGM was made either on Monday or Tuesday and removal on Thursday or Friday in order to avoid any overlap over weekend days. All calculations were derived from data obtained over a 48-h period during days 1 and 2 in order to avoid any bias due to both insertion and removal of the sensor. Sustained chronic hyperglycemia (ambient hyperglycemia) was assessed on study day 0 by HbA<sub>1c</sub> levels that were determined using a high-performance liquid chromatography assay (13–15). The intra- and interassay coefficients of variation were  $<2\%$  with a nondiabetic reference range of 16.7–32.1 mmol/mol (3.7–5.1%) HbA<sub>1c</sub>.

### **Analysis of the data obtained from the CGM**

The CGM was used for identifying and quantifying both the nocturnal nadir, premeal and postmeal peak glucose levels. Prebreakfast time points were determined in accordance with the data recorded by each participant in his/her own log book. All readings of CGM were centralized in Montpellier and concomitantly made by two investigators using the same methodology for analysis and interpretation of the data of the glycemic profiles from 2003 to 2011. All measurements provided by CGM are presented having averaged the data recorded on study days 1 and 2. This strategy was used because a prestudy analysis of the glucose profiles had indicated that the dawn phenomenon was subject to large interday fluctuations at an individual level. In the 248 subjects included in the present analysis, the comparison of the data recorded on study days 1 and 2 showed that the median of interday difference from nocturnal glucose nadir to prebreakfast glucose value was equal to 15.0 mg/dL (interquartile range 0–21.0 mg/dL). Given this observation and in order to attenuate the day-to-day fluctuations of the data of the glucose profiles including those of the dawn phenomenon, we therefore decided to conduct the final analysis of the glucose profiles after all data had been averaged

on the 2 consecutive days of the glucose monitoring.

The dawn phenomenon (i.e., the spontaneous glucose rise during early morning hours) was quantified by subtracting the glucose nadir from the glucose value observed just before the beginning of breakfast. Even though measurements of glucose in the interstitial fluid from CGM readings are lower than venous plasma glucose concentrations (16), it should be noted that in the current study, the dawn phenomenon was assessed from differences between interstitial values. The upward glycemic variation during the night was only considered a dawn phenomenon if its magnitude was above the stochastic spontaneous glucose fluctuations during the early morning period after an overnight fast. According to this remark, a threshold of 20 mg/dL was chosen because it appears more tenable than others that were previously used (7,8). This choice was based on three main principles. First, a value of 20 mg/dL approximates to the 95% CI of total intra- and interassay variability applied to a true fasting glucose concentration of 126 mg/dL (17). This value is comparable to those observed at prebreakfast times in the overall population and in the different groups of the current study (Table 1). Second, this value of 20 mg/dL is nearest to that recently observed for the mean magnitude of the dawn glucose rise in type 2 diabetes (9). Third, as indicated above and according to the calculations that were made by comparing the dawn glucose rises on study days 1 and 2, the median of interday difference was 15 mg/dL.

### **Assessment of the impact of the dawn phenomenon on the overall glucose exposure**

In order to assess the impact of the dawn phenomenon on the overall glucose exposure, the subjects of the total investigated population ( $n = 248$ ) and of the different groups selected by treatments were divided according to whether they exhibited or not a dawn glucose increase  $>20$  mg/dL. All separated patients were then matched for the nocturnal glucose nadir that was taken as reference for the calculation of the dawn glucose increment. The latter procedure was rendered necessary in order to align pairs of patients on the same glucose reference and to avoid any bias when comparing the data between individuals who exhibited a dawn phenomenon and those

**Table 1—Main clinical characteristics and treatments of patients in the overall population and in the different groups individualized according to whether patients were treated with diet alone, insulin sensitizers alone, and insulin secretagogues alone or in combination with insulin sensitizers**

Groups	Overall population	Diet alone	Insulin sensitizer alone	Insulin secretagogue alone or in combination with insulin sensitizers	P value
Number of patients tested	248	53	82	113	
Age (years)	59.9 (0.6)	58.1 (1.1)	59.0 (1.2)	61.5 (0.9)	NS
BMI (kg/m <sup>2</sup> )	30.2 (0.3)	29.9 (0.8)	31.1 (0.6)	29.7 (0.5)	NS
Sex ratio (male/female)	173/75	44/9	49/33	80/33	0.015
Total energy intake (kcal/day)	2,205 (22)	2,263 (56)	2,209 (38)	2,175 (32)	NS
Total carbohydrate intake (g/day)	275 (3)	283 (7)	276 (5)	272 (4)	NS
HbA <sub>1c</sub> (mmol/mol)	54.8 (0.6)	47.3 (1.3)	56.0 (0.7)	57.4 (0.9)	<0.0001
HbA <sub>1c</sub> (%)	7.16 (0.06)	6.48 (0.12)	7.28 (0.07)	7.40 (0.08)	<0.0001
Mean glucose value (mg/dL)					
Nocturnal nadir time	106.2 (2.2)	91.2 (4.2)	111.9 (3.6)	109.0 (3.0)	0.0006
Prebreakfast time	125.6 (2.1)	114.4 (3.9)	129.7 (3.4)	127.8 (3.5)	0.022
Peak postbreakfast time	199.2 (3.1)	190.9 (6.0)	191.5 (4.9)	208.1 (4.9)	0.024
Prelunch time	118.4 (2.1)	105.9 (3.5)	121.1 (3.5)	122.5 (3.3)	0.006
Peak postlunch time	167.1 (2.6)	164.7 (5.7)	163.2 (4.6)	171.2 (3.8)	NS
Predinner time	114.4 (1.9)	103.3 (3.5)	121.6 (3.4)	114.3 (2.8)	0.002
Peak postdinner time	167.9 (2.4)	162.2 (4.2)	172.8 (3.6)	167.1 (4.2)	NS
Averaged 24-h mean glucose concentration (mg/dL)	137.8 (1.9)	123.9 (3.1)	141.4 (3.6)	141.7 (2.9)	0.0007
Magnitude of the dawn phenomenon (mg/dL, median [interquartile range])	16.0 (0–31.5)	20.0 (0–37.2)	15.0 (0–28.0)	13.0 (0–30.2)	NS

Data are expressed as means (SEM) unless otherwise indicated. For magnitudes of the dawn phenomenon, the results are expressed as medians (interquartile range) since the data were not normally distributed. P values indicate the statistical significance for comparisons among means, ratios, and medians in the three groups selected by treatment.

who did not. Using these criteria, the numbers of subjects remaining in the different paired subsets after selection for the presence or absence of the dawn


phenomenon and after matching for nocturnal glucose nadir are indicated in Fig. 1. The impact of the dawn phenomenon on the overall glucose exposure was quantified

by comparing the mean differences in the averaged 24-h mean glucose concentrations and HbA<sub>1c</sub> levels between the paired subsets of subjects who were matched for glucose nadir and separated according to the presence or absence of dawn phenomenon.

**Statistical analysis**

Results are given as mean ± SEM or median with interquartile ranges as appropriate. For instance, the median was used for analyzing the magnitude of the dawn phenomenon (∂ glucose) since its distribution was asymmetrical and skewed toward low values. The Kruskal-Wallis test was used for multiple median comparisons of asymmetrical distributed data. The ANOVA test or the Student t test were used for comparison of means of normally distributed data, as appropriate. Analysis were performed with the STATVIEW statistical package for Macintosh (programs from SAS Institute, Cary, NC).

**RESULTS**—Clinical and laboratory data of the entire study population (n = 248) and for the three different groups selected by treatment are included in



**Figure 1—Steps used for analyzing the impact of the dawn phenomenon in the overall population and in the different groups selected by treatments. In the different groups including the overall population, the patients were secondarily separated into two paired subsets after selection for presence/absence of a dawn phenomenon (threshold set at 20 mg/dL) and after matching for nocturnal glucose nadir. Number of patients in each group and subset are indicated inside each square.**

Table 1, after exclusion of the patients who did not fulfill the selection criteria. Age and BMI, but not sex ratio, were similar in all groups. The mean maximum glucose concentrations of the circadian glycemic profiles were observed after breakfast during the morning period. In all groups, the prebreakfast mean glucose concentrations (i.e., the value after the overnight fast) were significantly higher ( $P < 0.0001$ ) than the nadir values observed during the nocturnal periods.

### Magnitude of the dawn phenomenon

The absolute median glucose increments ( $\Delta$  glucose, mg/dL) from nocturnal nadir to prebreakfast value did not statistically differ ( $P = 0.37$ ) when the different groups selected by categories of treatment were compared (Table 1). Slight but not significant differences ( $P = 0.14$ ) were observed across groups of subjects individualized according to their HbA<sub>1c</sub> levels: median  $\Delta$  glucose (interquartile range) 11.0 (0–26.8 mg/dL), 19.5 (0–33.0 mg/dL), and 18.0 (0–39.5 mg/dL) according to whether the subjects had HbA<sub>1c</sub> levels  $< 53$  mmol/mol ( $< 7\%$ ;  $n = 111$ ), between 53 and 62.9 mmol/mol (7–7.9%;  $n = 90$ ), and  $\geq 64$  mmol/mol ( $\geq 8\%$ ;  $n = 47$ ), respectively.

### Impact of the dawn phenomenon on the total glucose exposure

As indicated in Table 2, when the glucose threshold of the dawn phenomenon was set at 20 mg/dL, both the HbA<sub>1c</sub> levels and the averaged 24-h mean glucose values in the paired subsets of subjects matched for glucose nadir in the overall population ( $n = 136$ ) were statistically greater ( $P = 0.007$  and  $P = 0.0009$ , respectively) in those subjects who exhibited the dawn phenomenon compared with those who did not. The mean differences between the two paired subsets were  $4.3 \pm 1.3$  mmol/mol for HbA<sub>1c</sub> and  $12.4 \pm 2.4$  mg/dL for averaged 24-h mean intracutaneous glucose concentrations. An illustration of these results is given by the differences of the mean glycemic profiles obtained in the two paired subsets of participants included in the overall population after matching for nocturnal nadirs (Fig. 2A).

Considering the participants when selected by treatments, the differences were found to be less significant than in the overall population (Table 2). In the two paired subsets treated with diet alone, those who had a dawn glucose rise  $> 20$  mg/dL exhibited greater averaged 24-h mean glucose concentrations ( $P = 0.019$ ) than the subjects whose


glucose levels remained below this threshold (Table 2). By contrast, HbA<sub>1c</sub> levels were not significantly different. An illustration of the results of the mean glycemic profiles obtained in the two paired subsets of participants who were treated with dietary measures alone and matched for nocturnal nadirs is given in Fig. 2B. In the two remaining paired subsets (i.e., in the patients treated with OHAs), the HbA<sub>1c</sub> levels differed significantly, while the averaged 24-h mean glucose concentrations did not (Table 2). The highest difference of dawn impacts on 24-h mean glucose value between patients with/without a dawn phenomenon was observed in the subset of patients who were treated with diet alone:  $16.7 \pm 5.9$  mg/dL (Table 2). The impacts of the dawn phenomenon were less, although not significantly lower, in the pharmacologically treated subjects:  $11.2 \pm 5.3$  mg/dL in persons on insulin sensitizers alone and  $8.5 \pm 7.5$  mg/dL in those on insulin secretagogues alone or in combination with insulin sensitizers.

**CONCLUSIONS**—The present results, which were analyzed after a rigorous validation of glucose monitoring, indicate that in non-insulin-treated persons with type 2 diabetes, the median

Table 2—Impact of the dawn phenomenon on the total glucose exposure

Subsets selected in	HbA <sub>1c</sub> level (mmol/mol [%])				24-h mean glucose value (mg/dL)			
	Without DP	With DP	Impact of the DP	P value	Without DP	With DP	Impact of the DP	P value
The overall population								
Mean	51.6 (6.87)	55.9 (7.27)	4.3 (0.39)		124.7	137.1	12.4	
SEM	1.0 (0.09)	1.2 (0.11)	1.3 (0.12)		2.3	2.3	2.4	
Number tested	68	68	68	0.007	68	68	68	0.0009
Patients on diet alone								
Mean	44.4 (6.22)	48.4 (6.58)	4.0 (0.36)		111.5	128.3	16.7	
SEM	1.7 (0.15)	2.9 (0.26)	2.9 (0.26)		3.4	5.8	5.9	
Number tested	15	15	15	0.25	15	15	15	0.019
Patients on insulin sensitizers alone								
Mean	53.5 (7.04)	57.7 (7.43)	4.2 (0.38)		124.7	135.9	11.2	
SEM	1.4 (0.12)	1.4 (0.12)	2.3 (0.21)		3.8	4.9	5.3	
Number tested	18	18	18	0.037	18	18	18	0.080
Patients on insulin secretagogues alone or combination with insulin sensitizers								
Mean	54.7 (7.15)	60.2 (7.66)	5.5 (0.50)		134.8	143.3	8.5	
SEM	1.8 (0.16)	2.1 (0.19)	3.3 (0.30)		4.8	5.6	7.5	
Number tested	26	26	26	0.047	26	26	26	0.26

The impact was assessed by calculating the differences between HbA<sub>1c</sub> levels and averaged 24-h mean glucose concentration in subsets of patients with/without a dawn phenomenon (threshold at 20 mg/dL) and matched for nocturnal nadir. P values indicate statistical significances of differences between subsets. HbA<sub>1c</sub> levels are dually expressed as mmol/mol and percentages (between parentheses for the latter). DP, dawn phenomenon.



**Figure 2**—Mean averaged 24-h continuous glucose profiles in the two paired subsets of patients derived from either the overall population (A) ( $n = 68$  in each subset) or the group treated with diet alone (B) ( $n = 15$  in each subset). The subsets were selected after patients had been separated for the presence/absence of a dawn phenomenon. Solid curves, subsets of patients with the presence of a dawn phenomenon; dotted curves, subsets of patients with the absence of a dawn phenomenon.

magnitude of the dawn glucose increase is  $\sim 16$  mg/dL and relatively stable across the groups of subjects selected either by categories of treatment or HbA<sub>1c</sub> levels. In the population considered as a whole and in the different groups selected by treatments, the highest peak glucose value of the circadian glucose profile was observed during the postbreakfast period. This observation is in agreement with previous reports (17,18). These excessive post-breakfast glucose excursions correspond to the so-called “extended dawn phenomenon,” which is characterized by the fact that the glucose tolerance is worse in the early morning than at any other time of the day (19). The dawn and extended dawn phenomena behave conjointly since they depend on an increase in both hepatic glucose output/neoglucogenesis and peripheral insulin resistance in the early morning period (20,21). Consequently, it is important first to assess whether the dawn phenomenon exerts a remnant effect on the glycemic profile and further to quantify this impact on the overall glucose exposure which was the main purpose of this study. The comparison of the subsets matched for the nocturnal glucose nadir and separated by the presence/absence of a dawn phenomenon showed that the differences in HbA<sub>1c</sub> levels and mean glucose concentrations were  $\sim 4$  mmol/mol (0.4%) and 12 mg/dL, respectively. However, it should be noted that discrepancies in statistical significances were observed in the different groups. In the subjects treated with diet alone, the differences were only significant for the mean glucose concentrations and not for

HbA<sub>1c</sub>, while the reverse was observed in the patients on OHAs. Such discrepancies could be due to the reduction in sample size when participants were divided into subsets. Also, it is always difficult to extrapolate to prolonged periods of time ( $\sim 3$  months for the HbA<sub>1c</sub> [13–15]) the effect of the presence or absence of the dawn phenomenon, as its assessment on 2 consecutive days is not necessarily a reflection of what happens during longer periods of time. The dawn glucose rise from nocturnal nadir to prebreakfast time is subject to large day-to-day fluctuations, supported by the fact that in the current study, the median of between-day difference in the magnitude of the dawn phenomenon is as high as 15.0 mg/dL. Therefore, averaging the dawn phenomenon on 2 consecutive days and assessing its impact on the averaged 2-day mean glucose concentrations and HbA<sub>1c</sub> levels is an approach that was designed for attenuating its interday variability. Extending the CGM for longer periods risked the loss of both reliability of the glucose sensor and acceptance of the monitoring device by the participants. Our findings are supported by the fact that the impact of the dawn phenomenon in the overall population (12 mg/dL on the mean glucose concentration and 4 mmol/mol [i.e., 0.4% on HbA<sub>1c</sub>]) is in broad agreement with the relationship that was previously established by Nathan et al. (22) in the A1C-Derived Average Glucose study (i.e., any increment of 29 mg/dL in mean glucose concentration corresponds to a 1% increment in HbA<sub>1c</sub>).

In conclusion, the remnant effect of the dawn phenomenon on the overall diabetic control is  $\sim 4$  mmol/mol (i.e.,  $\sim 0.4\%$  HbA<sub>1c</sub>). Taking as reference the paired subsets of participants treated with diet alone, it appears that the dawn phenomenon is already present in those who are free of any pharmacological treatment with antidiabetes agents. Even though its impact seems to be slightly lower in individuals on OHAs, our results indicate that the dawn phenomenon has a remnant impact in subjects treated with our current oral antidiabetes armamentarium (23).

**Acknowledgments**—This study was supported by academic funds provided by the Universities of Montpellier I and Cardiff.

No potential conflicts of interest relevant to this article were reported.

L.M. contributed to the study design, participated in patient clinical care, analyzed data, and wrote, reviewed, and edited the manuscript. C.C. analyzed data and reviewed and edited the manuscript. S.D. contributed to the study design and reviewed the manuscript. D.O. contributed to the study design, participated in patient clinical care, and reviewed the manuscript. L.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

## References

- Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic

- intraday blood glucose variation. *Diabetes Care* 1981;4:579–585
- Schmidt MI, Lin QX, Gwynne JT, Jacobs S. Fasting early morning rise in peripheral insulin: evidence of the dawn phenomenon in nondiabetics. *Diabetes Care* 1984;7:32–35
  - Buckingham B, Black J, Wilson DM. Continuous glucose monitoring. *Curr Opin Endocrinol Diabetes* 2005;12:273–279
  - Skyler JS. Continuous glucose monitoring: an overview of its development. *Diabetes Technol Ther* 2009;11(Suppl. 1):S5–S10
  - Bolli GB, Gerich JE. The “dawn phenomenon”—a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. *N Engl J Med* 1984;310:746–750
  - Atia JA, Luzio S, Owens DR. The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients. *Diabetes Res Clin Pract* 1992;16:183–190
  - Carroll MF, Hardy KJ, Burge MR, Schade DS. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. *Diabetes Technol Ther* 2002;4:595–605
  - Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. *Endocr Pract* 2005;11:55–64
  - Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age. *Diabetes Care* 2012;35:2597–2599
  - Schofield WN, Schofield C, James WPT. Basal metabolic rate—review and prediction, together with an annotated bibliography of source material. *Hum Nutr Clin Nutr* 1985;39C(Suppl. 1):1–96
  - World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. *JAMA* 1997;277:925–926
  - Directive 2001/20/CE of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical trials on medicinal products for human use. *Off J Eur Communities* 2001;L121:33–44
  - Gorus F, Mathieu C, Gerlo E. How should HbA<sub>1c</sub> measurements be reported? *Diabetologia* 2006;49:7–10
  - Sacks DB, Bruns DE, Goldstein DE, MacLaren NK, McDonald JM, Parrott M. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). *Diabetes Care* 2002;25:750–786
  - Sacks DB. Measurement of hemoglobin A<sub>1c</sub>: a new twist on the path to harmony. *Diabetes Care* 2012;35:2674–2680
  - Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? *Diabetes Care* 2002;25:889–893
  - Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. *Diabetes Care* 1999;22:394–398
  - Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. *Diabetes Care* 2002;25:737–741
  - Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. *Diabetes Care* 2007;30:263–269
  - Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. *Diabetes* 1996;45:1044–1050
  - Perriello G, Pampanelli S, Del Sindaco P, et al. Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. *Diabetes* 1997;46:1010–1016
  - Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose (ADAG) Study Group. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008;31:1473–1478
  - Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2012;55:1577–1596